Combined Inhibition Of CDK4/6 And PI3K Pathways Shows Potential In Ewing Sarcoma

This study published in Translational Oncology explores new drug combinations to treat Ewing Sarcoma. Traditional treatments are often ineffective for patients with advanced or returning disease and direct targeting of the primary cancer-driving protein (EWSR1::FLI1) has proven notoriously difficult. To find a solution, researchers screened 180 combinations of 28 existing drugs that were either FDA-approved or in late-stage clinical development. They discovered that combining Copanlisib (a PI3K inhibitor) with Ribociclib (a CDK4/6 inhibitor) created a powerful synergistic effect that successfully blocked the cancer’s ability to survive and replicate.

Through detailed cellular and genetic analysis, the researchers demonstrated that the Copanlisib-Ribociclib combination attacks the tumor on multiple fronts. Ribociclib primarily freezes the cancer cells to stop them from dividing while Copanlisib dramatically amplifies cell death (apoptosis). Together, the drugs shut down vital cellular pathways responsible for cell cycle regulation and tumor growth. When tested in animal models this dual-therapy approach significantly prolonged survival compared to using either drug alone providing a highly promising, readily available blueprint for future pediatric clinical trials.

Read the full article